This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® Genitourinary Cancers Symposium 2023
Presentations
Enfortumab Vedotin | Urothelial Cancer | Abstract #439
Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the Phase 1b/2 EV-103 Cohort K study
Enfortumab Vedotin | Urothelial Cancer | Abstract #499
Enfortumab vedotin (EV) alone or in combination w/ pembrolizumab (P) in previously untreated cisplatin-ineligible patients w/ locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 Cohort K
Enfortumab Vedotin | Bladder Cancer | Abstract #TPS582
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) (Trial in Progress)
Enfortumab Vedotin | Bladder Cancer | Abstract #TPS585
Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)
Enfortumab Vedotin | Bladder Cancer | Abstract #TPS588
Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304